ACCRU-LY-1601: Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma (clinicaltrials.gov) - Sep 15, 2026 - P2 | N=83 | Active, not recruiting | Sponsor: Academic and Community Cancer Research United | Trial completion date: Jul 2026 ➔ Jul 2027
Trial completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology
|